Medline Reports Fourth Quarter and Full Year 2025 Results

Rhea-AI Summary

Medline (Nasdaq: MDLN) reported strong full year 2025 results, completed an initial public offering, and issued 2026 guidance.

Key metrics: Q4 net sales $7.8B (+14.8%), Q4 net income $180M (-37.7%), full year net sales $28.4B (+11.5%), full year Adjusted EBITDA $3.5B (+3.2%). Company expects 2026 Organic Sales growth of 8%–9% and Adjusted EBITDA of $3.5–$3.6B.

Positive

• Completed initial public offering in Q4 2025
• Full year net sales $28.4B (+11.5%)
• Full year Adjusted EBITDA $3.5B (+3.2%)
• Organic Sales growth 10.5% in 2025
• Net cash from operations $1.7B; Free Cash Flow $1.3B

Negative

• Full year net income decreased 3.6%
• Q4 net income declined 37.7% to $180M
• Higher costs from tariffs and IPO-related expenses
• Working capital increased due to receivables and inventories

Key Figures

Q4 2025 net sales: $7.8 billion (up 14.8%) Q4 2025 net income: $180 million (down 37.7%) Full-year 2025 net sales: $28.4 billion (up 11.5%) +5 more

8 metrics

Q4 2025 net sales $7.8 billion (up 14.8%) Versus $6.8 billion in Q4 2024; Organic Sales up 14.4%

Q4 2025 net income $180 million (down 37.7%) Versus $289 million in Q4 2024; pressured by tariffs and higher costs

Full-year 2025 net sales $28.4 billion (up 11.5%) Versus $25.5 billion in full-year 2024; Organic Sales up 10.5%

Full-year 2025 net income $1.2 billion (down 3.6%) Versus $1.2 billion in full-year 2024; impacted by tariffs and IPO costs

Full-year 2025 Adjusted EBITDA $3.5 billion (up 3.2%) Versus $3.4 billion in full-year 2024

2025 operating cash flow $1.7 billion Net cash provided by operating activities in full-year 2025

2025 Free Cash Flow $1.3 billion Full-year 2025 Free Cash Flow after capital expenditures

2026 Adjusted EBITDA guidance $3.5–$3.6 billion Full-year 2026 outlook provided on a non-GAAP basis

Market Reality Check

Price: $49.99 Vol: Volume 3,080,922 is 1.05x...

normal vol

$49.99 Last Close

Volume Volume 3,080,922 is 1.05x the 20-day average of 2,937,271, indicating only slightly elevated trading activity ahead of and around the earnings release. normal

Technical Shares at $49.99 are trading above the 200-day MA of $44.10 and sit 0.6% below the 52-week high of $50.28, reflecting a strong pre-earnings uptrend.

Peers on Argus

No peers were flagged in the momentum scanner and no same-day peer headlines wer...

No peers were flagged in the momentum scanner and no same-day peer headlines were provided, suggesting the modest 0.71% move was driven primarily by Medline-specific earnings and guidance rather than a sector-wide shift.

Historical Context

4 past events · Latest: Feb 18 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Feb 18	Conference participation	Positive	+3.4%	Announcement of CEO and CFO presenting at Barclays healthcare conference.
Jan 28	Earnings date notice	Neutral	-4.3%	Company set the date and time for Q4 and full-year 2025 results.
Dec 30	Conference participation	Positive	+0.2%	Management scheduled to present at the J.P. Morgan Healthcare Conference.
Dec 18	IPO completion	Positive	-3.7%	Closing of upsized IPO and full exercise of underwriters’ option.

Pattern Detected

Recent history shows generally positive or neutral news often aligning with modest positive price moves, while the upsized IPO headline saw a negative reaction, indicating some sensitivity to capital structure or supply overhang headlines.

Recent Company History

Over the last few months, Medline has transitioned from IPO completion to active investor engagement. The upsized IPO closing on Dec 18, 2025 was followed by conference participation announcements at J.P. Morgan and Barclays, supporting visibility as a newly public company. An earnings-date notice on Jan 28, 2026 drew a negative reaction, while conference headlines produced small gains. Today’s Q4/FY 2025 earnings and 2026 guidance update build directly on that IPO and conference cadence, adding the first full-year public-company performance snapshot.

Market Pulse Summary

This announcement details Medline’s first full-year results as a public company, with Q4 2025 net sa...

Analysis

This announcement details Medline’s first full-year results as a public company, with Q4 2025 net sales of $7.8 billion and full-year sales of $28.4 billion, both growing double digits. Net income declined as tariffs and IPO-related costs weighed on margins, while 2025 Adjusted EBITDA reached $3.5 billion. Guidance calling for 2026 Adjusted EBITDA of $3.5–$3.6 billion places focus on how effectively Medline manages cost inflation and executes on new customer signings.

Key Terms

adjusted EBITDA, organic sales, free cash flow, initial public offering, +1 more

5 terms

adjusted EBITDA financial

"Fourth quarter Adjusted EBITDA1 of $805 million, approximately flat"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

organic sales financial

"with Organic Sales¹ increasing 14.4%"

Organic sales are the change in a company’s revenue that comes from its existing business operations, excluding effects of acquisitions, divestitures, and currency swings. Think of it like measuring how much a garden grows from the plants you already tended, rather than adding new pots; investors use organic sales to judge whether demand and core business performance are genuinely improving or if growth is driven by one‑time deals or accounting shifts.

free cash flow financial

"Free Cash Flow¹ for the full year of 2025 was $1.3 billion"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

initial public offering financial

"completion of our successful initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

non-GAAP financial measures financial

"are non-GAAP financial measures. See discussion of these measures"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

AI-generated analysis. Not financial advice.

• Delivered strong full year 2025 results
• Completed Initial Public Offering
• Introduced full year 2026 guidance
  
  
• Fourth quarter net sales of $7.8 billion, an increase of 14.8%
  
• Fourth quarter net income of $180 million, a decrease of 37.7%
• Fourth quarter Adjusted EBITDA¹ of $805 million, approximately flat
  
  
• Full year net sales of $28.4 billion, an increase of 11.5%
  
• Full year net income of $1.2 billion, a decrease of 3.6%
• Full year Adjusted EBITDA¹ of $3.5 billion, an increase of 3.2%
  

NORTHFIELD, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care², today reported its operating results for the three months and full year ended December 31, 2025.

“We delivered strong fourth quarter results, concluding a successful 2025 with $2.4 billion in total new customer signings³,” said Jim Boyle, Chief Executive Officer of Medline. “This performance reflects the confidence customers place in our value, service and reliability, and our unique capability to support health systems across the entire continuum of care.”

“The quarter also marked a major milestone with the completion of our successful initial public offering. Becoming a public company amplifies our voice and strengthens our foundation by enabling continued investments to drive growth and deliver greater value to customers. We expect our momentum to continue, and with our scale, broad product portfolio, and unmatched distribution footprint, we believe we are well positioned for sustainable long‑term growth.”

Fourth Quarter 2025 Results

Net sales in the fourth quarter 2025 were $7.8 billion, an increase of 14.8%, compared to $6.8 billion in the fourth quarter 2024, with Organic Sales¹ increasing 14.4%. This was primarily driven by increased volumes, with strong growth from both the Medline Brand and Supply Chain Solutions segments.

Fourth quarter 2025 net income was $180 million, a decrease of 37.7%, compared to $289 million in the fourth quarter 2024, driven by higher costs of goods sold due to tariffs and higher operating costs, including investments in headcount and IPO-related expenses, partially offset by higher net sales.

Fourth quarter 2025 Adjusted EBITDA¹ was $805 million, a decrease of 0.6%, compared to the fourth quarter 2024, driven by higher costs of goods sold due to tariffs and higher operating costs, including investments in headcount, partially offset by higher net sales.

Full Year 2025 Results

Net sales for the full year 2025 were $28.4 billion, an increase of 11.5%, compared to $25.5 billion for full year 2024, with Organic Sales¹ increasing 10.5%. This was primarily driven by increased volumes, with strong growth from both the Medline Brand and Supply Chain Solutions segments.

Full year 2025 net income was $1.2 billion, a decrease of 3.6% compared to $1.2 billion for full year 2024, driven by higher costs of goods sold due to tariffs and higher operating costs, including investments in headcount and IPO‑related expenses, partially offset by higher net sales.

Full year 2025 Adjusted EBITDA¹ was $3.5 billion, an increase of 3.2%, compared to $3.4 billion for full year 2024, driven by higher net sales, partially offset by higher costs of goods sold due to tariffs and higher operating costs, including investments in headcount.

Net cash provided by operating activities for the full year of 2025 was $1.7 billion, primarily driven by net income, excluding the impact of non-cash items, partially offset by changes in working capital primarily due to increased trade accounts receivable related to net sales growth, increased inventories including tariff impacts, and a net cash outflow in the second quarter of 2025 related to legal settlements.

Free Cash Flow¹ for the full year of 2025 was $1.3 billion, primarily driven by net cash provided by operating activities, offset by capital expenditures related to continued enhancements and automation in our distribution centers and investments in our kitting manufacturing facilities.

2026 Guidance
For full year 2026, the Company expects Organic Sales⁴ growth of 8% to 9% and Adjusted EBITDA⁴ of $3.5 to $3.6 billion.

Webcast and Conference Call Instructions
The Company will host a live conference call and question and answer session with investors and analysts on February 25, 2026, at 8:30 a.m. CT / 9:30 a.m. ET to discuss its fourth quarter and full year 2025 earnings results. The webcast can be accessed through Medline’s Investor Relations website at ir.medline.com. A replay of the call will be available following the event through the same website.

End Notes and Use of Non-GAAP Financial Measures
Certain amounts and percentages presented in this press release have a rounding element. As a result, the sum of the components may not equal the totals due to rounding.

(1) Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, and Net Leverage are non-GAAP financial measures. See discussion of these measures and reconciliations to GAAP at the end of this press release for more information.
(2) Based on our 2025 net sales relative to the publicly reported net sales of med-surg products by companies that are both med-surg manufacturers and distributors.
(3) Total new customer signings refers to the estimated annual contract value of all new contracts entered into during a given year by new customers or by existing customers who are expanding their relationship with Medline, excluding renewals and extensions.
(4) Guidance for Adjusted EBITDA and Organic Sales is provided on a non-GAAP basis only because certain information necessary to calculate the most comparable GAAP measure is unavailable due to the uncertainty and inherent difficulty of predicting the occurrence and the future financial statement impact of such items impacting comparability, including, but not limited to, inventory-related adjustments, stock-based compensation, litigation (gains) charges, net, transaction-related costs, the impact of currency, and other non-core (gains) charges, among other items. Therefore, as a result of the uncertainty and variability of the nature and amount of future adjustments, which could be significant, the Company is unable to provide a reconciliation of these measures with reasonable certainty and without unreasonable effort.

Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to the Company’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond the Company’s control, that could cause actual results to differ materially.

Factors that may cause actual results to differ from expected results include, but are not limited to the Company’s reliance on the proper function, security, and availability of its information technology systems and data, as well as those of third parties throughout its global supply chain, and the impact of a breach, cyber-attack, or other disruption to these systems or data; inherent risks in the Company’s global operations; the Company’s ability to comply with extensive and complex laws and governmental regulations and the cost of adverse regulatory actions; the cost of compliance with environmental, health, and safety requirements; the Company’s ability to realize the expected benefits from the entry into new or amended contracts, planned cost savings, and business improvement initiatives; consolidation in the healthcare industry; foreign currency exchange rate fluctuations; increased inflationary pressures; uncertain global macro-economic and political conditions; the impact of government-imposed import policies, tariffs, and legislation; competition and accelerating price pressure in the Company’s markets; the Company’s ability to comply with anti-bribery laws, anti-corruption laws, and those laws and regulations pertaining to economic sanctions; the Company’s ability and the ability of third parties it works with to comply with complex and rapidly evolving data privacy, security, and data protection laws and regulations; the risks of increasing use of artificial intelligence, automated decision-making and machine learning technology; the impact of tax legislation and audits by tax authorities; changes to the U.S. and global healthcare environments; the Company’s reliance on third-party manufacturers, certain significant suppliers and third-party shippers; the impact of price fluctuations of key commodities and other factors of production, including labor and transportation, on the Company’s manufacturing business; the impact of significant challenges or delays in the Company’s sourcing of new products and technologies; the Company’s concentration in and dependence on certain healthcare provider customers and group purchasing organizations; the Company’s ability to attract, develop and retain key employees; the Company’s reliance on the proper functioning of critical facilities and distribution networks; the cost of litigation brought by third parties claiming infringement, misappropriation, or other violation by the Company of their intellectual property rights; potential requirements to recognize impairment charges related to goodwill, identified intangible assets, and fixed assets; the Company’s ability to derive fully the anticipated benefits from the Company’s existing or future acquisitions, joint ventures, investments, dispositions, or other strategic transactions; quality problems, recalls, and product liability claims; climate change and legal, regulatory, and market measures to address climate change; the Company’s aspirations, goals, and disclosures related to ESG and sustainability matters; the unfavorable outcome of legal proceedings it is involved in; the Company’s ability to comply with laws and regulations relating to reimbursement of healthcare goods and services; the Company’s ability and the ability of third parties it works with to reduce expenses if the Company experiences decreasing prices for the Company’s goods and services; the adequacy of the Company’s insurance program to cover future losses; the Company’s ability to obtain, maintain, protect, and enforce its intellectual property rights; the Company’s dependence on positive perceptions of its reputation; the Company’s substantial indebtedness and ability to incur substantially more debt; the Company’s exposure to the financial risks associated with interest rate fluctuations on its variable rate debt; restrictive covenants in the Company’s debt agreements, which may restrict the Company’s ability to pursue its business strategies and its ability to comply with them; the dual class structure of the Company’s common stock; the volatility of the market price of the Company’s Class A common stock; and other factors. For additional information on these and other risks that could affect the Company's forward-looking statements, see the Company's risk factors discussed in its filings with the U.S. Securities and Exchange Commission (the “SEC”), as such risk factors may be updated from time to time.

The Company disclaims any intent or obligation to update, revise, or withdraw any forward-looking statement in this press release, except as required by applicable law or regulation.

The Company uses its investor relations website at ir.medline.com, press releases, public conference calls and webcasts, and social media as routine channels of distribution to communicate important, and often material, information about Medline to investors and the public, including information about its financial performance and results, analyst and investor presentations, investor days, products, solutions, sustainability initiatives, and corporate governance practices. You are encouraged to follow these channels, in addition to our SEC filings, for timely information about the Company. The information on the Company’s websites is not part of this press release and is not incorporated by reference into any filings the Company makes with the SEC.

Non-GAAP Financial Measures
The non-GAAP financial measures provided in this press release should be viewed in addition to, and not as an alternative for, results prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

To supplement the financial information provided, the Company has presented Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, and Net Leverage, which are considered non-GAAP financial measures. The non-GAAP financial measures presented may differ from similarly titled non-GAAP financial measures presented by other companies, and other companies may not define these non-GAAP financial measures in the same way. These measures are not substitutes for their comparable GAAP financial measures, such as net income/(loss), net income margin, net cash from operating activities, net sales, or other measures prescribed by GAAP, and there are limitations to using non-GAAP financial measures.

Management uses these non-GAAP financial measures to assist in comparing the Company’s performance on a consistent basis for purposes of business decision making by removing the impact of certain items that management believes do not directly reflect the Company’s ongoing operating performance. The Company believes Organic Sales, Adjusted EBITDA, and Adjusted EBITDA Margin provide important comparability of ongoing operating performance, allowing investors and management to assess the Company’s operating performance on a consistent basis. The Company believes Free Cash Flow and Net Leverage provide a measure of the Company’s core operating performance, the cash-generating capabilities of the Company’s business operations, and are factors used in determining the Company’s borrowing capacity and the amount of cash available for debt repayments, acquisitions, and other corporate purposes.

Management believes that presenting the Company’s non-GAAP financial measures is useful to investors because it (i) provides investors with meaningful supplemental information regarding financial performance by excluding certain items that we do not consider indicative of our ongoing operating performance, (ii) permits investors to view performance using the same tools that management uses to budget, make operating and strategic decisions, and evaluate historical performance, and (iii) otherwise provides supplemental information that may be useful to investors in evaluating the Company’s results. The Company believes that the presentation of these non-GAAP financial measures, when considered together with the corresponding GAAP financial measures and the reconciliations to those measures, provides investors with additional understanding of the factors and trends affecting the Company’s business than could be obtained absent these disclosures.

Definitions
Organic Sales is defined as net sales excluding, when they occur, the impact of acquisitions, divestitures, and changes in foreign exchange rates from the net sales changes. The changes in foreign currency exchange rates from the net sales changes are calculated by translating current period GAAP results at the prior period foreign currency exchange rates and comparing these amounts to the current period GAAP results at the current period foreign currency exchange rates.

Adjusted EBITDA is defined as net income (loss) adjusted for (i) interest expense, net, (ii) provision for income taxes, (iii) depreciation and amortization, (iv) inventory-related adjustments, (v) stock-based compensation, (vi) litigation (gains) charges, net, (vii) transaction-related costs, and (viii) other non-core (gains) charges. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by net sales.

Free Cash Flow is defined as net cash provided by/(used for) operating activities less net capital expenditures. The use of this non-GAAP measure does not imply or represent the residual cash flow for discretionary expenditures since the Company has certain non-discretionary obligations such as debt service that are not deducted from the measure.

Net Leverage is defined as net debt (total debt less cash, cash equivalents and short-term investments) divided by Adjusted EBITDA.

Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its unique offering of world-class products, supply chain resilience and clinical practice expertise, Medline delivers improved clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the Company employs over 45,000 people worldwide and operates in over 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com.

Investor Relations:
Karen King
Global Head of Investor Relations

Patrick Flaherty
Director, Investor Relations

(847) 247-7222
IR@medline.com

Media Relations:
Ben Fox
Vice President, Corporate Communications

(224) 327-9999
media@medline.com 

Financial Tables

CONSOLIDATED STATEMENTS OF INCOME
(in millions, except per share earnings)	Three months ended (Unaudited)														Year ended
	December 31, 2025				December 31, 2024				$ Change				% Change		December 31, 2025				December 31, 2024			$ Change				% Change
Net sales	$	7,787			$	6,784			$	1,003			14.8%		$	28,432			$	25,507		$	2,925			11.5%
Cost of goods sold		5,873				4,933				940			19.1%			20,914				18,531			2,383			12.9%
Gross profit		1,914				1,851				63			3.4%			7,518				6,976			542			7.8%
Gross margin %		24.6	%			27.3	%									26.4%				27.3%
Operating expense
Selling, general and administrative expenses		1,265				1,164				101			8.7%			4,524				4,108			416			10.1%
Amortization of intangible assets		176				177				(1	)		(0.6)%			704				685			19			2.8%
Other operating expenses		48				18				30			NM(2)			78				37			41			NM(2)
Total operating expense		1,489				1,359				130			9.6%			5,306				4,830			476			9.9%
Operating income		425				492				(67	)		(13.6)%			2,212				2,146			66			3.1%
Operating margin %		5.5	%			7.3	%									7.8%				8.4%
Other expense
Interest expense, net		(166	)			(209	)			43			(20.6)%			(812)				(864)			52			(6.0)%
Other expense, net		(58	)			(8	)			(50	)		NM(2)			(64)				(43)			(21)			48.8%
Foreign exchange gain (loss), net		5				30				(25	)		(83.3)%			(88)				7			(95)			NM(2)
Total other expense		(219	)			(187	)			(32	)		17.1%			(964)				(900)			(64)			7.1%
Income before income taxes		206				305				(99	)		(32.5)%			1,248				1,246			2			0.2%
Provision for income taxes		26				16				10			62.5%			91				46			45			97.8%
Net income		180				289				(109	)		(37.7)%			1,157				1,200			(43)			(3.6)%
Net income %		2.3	%			4.3	%									4.1%				4.7%
Net loss attributable to noncontrolling interests		(2	)			—				(2	)		NM(2)			(2)				—			(2)			NM(2)
Net income attributable to Medline Inc.	$	182			$	—			$	182			NM(2)		$	1,159			$	—		$	1,159			NM(2)
Net loss per share attributable to Medline Inc.(1)
Basic and diluted	$	(0.01	)		N/A										$	(0.01)			N/A
Weighted average number of Class A common shares outstanding(1)
Basic and diluted		810			N/A											810			N/A

⁽¹⁾ Represents net loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding for the period from December 17, 2025, the date after the SEC declared effective the Company's Registration Statement on S-1 filed in connection with its IPO, through December 31, 2025, the period following the reorganization transactions and initial public offering.
⁽²⁾ Not Meaningful

CONSOLIDATED BALANCE SHEETS
(in millions, except per share amounts)	As of December 31, 2025				As of December 31, 2024
ASSETS
Current assets
Cash and cash equivalents	$	1,939			$	199
Trade accounts receivable, net of allowance for credit losses of $152 and $108 as of December 31, 2025 and 2024, respectively		3,533				3,219
Inventories		4,769				4,456
Other current assets		438				398
Total current assets		10,679				8,272
Property, plant, and equipment, net		4,778				4,595
Other non-current assets
Goodwill		8,079				8,065
Intangible assets, net		13,893				14,559
Deferred tax assets		583				—
Other long-term assets		472				487
Total other non-current assets		23,027				23,111
Total assets	$	38,484			$	35,978
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY / PARTNERS’ CAPITAL
Current liabilities
Current portion of long-term borrowings and other short-term borrowings	$	77			$	78
Accounts payable		961				869
Accrued expenses and other current liabilities		1,452				1,493
Total current liabilities		2,490				2,440
Non-current liabilities
Long-term borrowings, less current portion		12,484				16,416
Tax receivable agreement liability		3,542				—
Other long-term liabilities		682				598
Total non-current liabilities		16,708				17,014
Total liabilities	$	19,198			$	19,454
Commitments and contingencies
Mezzanine equity		—				366
Stockholders’ equity / partners’ capital
Class A common stock, par value $0.0001 per share; 50,000 shares authorized; 812 and no shares issued and outstanding as of December 31, 2025 and 2024, respectively		—				—
Class B common stock, par value $0.0001 per share; 50,000 shares authorized; 502 and no shares issued and outstanding as of December 31, 2025 and 2024, respectively		—				—
Preferred stock, par value $0.0001; 5,000 shares authorized; no shares issued and outstanding		—				—
Additional paid-in capital		10,717				—
Accumulated deficit		(7	)			—
Partners’ capital		—				16,147
Accumulated other comprehensive income		27				11
Total Medline Inc. stockholders’ equity / partners’ capital		10,737				16,158
Noncontrolling interests		8,549				—
Total stockholders’ equity / partners’ capital		19,286				16,158
Total liabilities, stockholders’ equity and mezzanine equity / partners’ capital	$	38,484			$	35,978

Consolidated Cash Flow Highlights

($ millions)	Year ended
	December 31, 2025				December 31, 2024				$ Change				% Change
Net cash provided by operating activities	$	1,744			$	1,769			$	(25	)		(1.4)%
Net cash used in investing activities		(474	)			(1,493	)			1,019			(68.3)%
Net cash provided by (used in) financing activities		399				(1,613	)			2,012			NM(1)
Effect of exchange rate changes		23				2				21			NM(1)
Net change in cash, cash equivalents and restricted cash	$	1,692			$	(1,335	)		$	3,027			NM(1)

⁽¹⁾ Not Meaningful

Segment Net Sales and Adjusted EBITDA Margin
(unaudited)

($ millions, except percentages)	Three months ended														Year ended
	December 31, 2025				December 31, 2024				$ Change				% Change		December 31, 2025				December 31, 2024				$ Change				% Change
Medline Brand segment
Net sales	$	3,723			$	3,329			$	394			11.8%		$	13,720			$	12,515			$	1,205			9.6%
Adjusted EBITDA		793				824				(31	)		(3.8)%			3,334				3,269				65			2.0%
Adjusted EBITDA Margin		21.3	%			24.8	%									24.3	%			26.1	%
Supply Chain Solutions segment
Net sales	$	4,064			$	3,455			$	609			17.6%		$	14,712			$	12,992			$	1,720			13.2%
Adjusted EBITDA		217				168				49			29.2%			805				647				158			24.4%
Adjusted EBITDA Margin		5.3	%			4.9	%									5.5	%			5.0	%
Corporate & Other(1)	$	(205	)		$	(182	)		$	(23	)		12.6%		$	(672	)		$	(555	)		$	(117	)		21.1%

⁽¹⁾ The organizational structure includes Corporate & Other which consists of expenses related to centralized corporate functions, such as finance, information technology, legal, human resources, and internal audit.

Reconciliation of Net Sales to Organic Sales
(unaudited)

	Three months ended						Year ended
($ millions, except percentages)	Amount			Percentage			Amount			Percentage
Net sales for period ended December 31, 2025	$	7,787					$	28,432
Net sales for period ended December 31, 2024		6,784						25,507
Net sales growth		1,003		14.8	%			2,925		11.5	%
Impact of acquisitions		10		0.1	%			237		0.9	%
Impact from changes in foreign exchange rates		17		0.3	%			12		0.1	%
Organic Sales	$	976		14.4	%		$	2,676		10.5	%

Reconciliation of Net Income to Adjusted EBITDA and Net Leverage
(unaudited)

		Three months ended														Year ended
($ millions, except percentages)		December 31, 2025				December 31, 2024				$ Change				% Change		December 31, 2025				December 31, 2024				$ Change				% Change
Net income		$	180			$	289			$	(109	)		(37.7)%		$	1,157			$	1,200			$	(43	)		(3.6)%
Interest expense, net			166				209				(43	)		(20.6)%			812				864				(52	)		(6.0)%
Provision for income taxes			26				16				10			62.5%			91				46				45			97.8%
Depreciation and amortization			261				254				7			2.8%			1,011				977				34			3.5%
Inventory-related adjustments (1)			45				11				34			NM(5)			83				78				5			6.4%
Stock-based compensation expense			27				11				16			NM(5)			79				61				18			29.5%
Litigation charges (gains), net (2)			14				—				14			NM(5)			(33	)			2				(35	)		NM(5)
Transaction-related costs (3)			23				9				14			NM(5)			58				18				40			NM(5)
Other non-core charges (4)			63				11				52			NM(5)			209				115				94			81.7%
Adjusted EBITDA		$	805			$	810			$	(5	)		(0.6)%		$	3,467			$	3,361			$	106			3.2%
Net income margin			2.3	%			4.3	%									4.1	%			4.7	%
Adjusted EBITDA Margin			10.3	%			11.9	%									12.2	%			13.2	%
Total debt																$	12,755			$	16,757				(4,002	)		(23.9)%
Less: Cash and cash equivalents																	1,939				199				1,740			NM(5)
Net debt																$	10,816			$	16,558				(5,742	)		(34.7)%
Net Leverage																	3.1				4.9

 

(1)	Includes inventory adjustment associated with non-cash last-in, first-out (“LIFO”) reserves. Inventory adjustments were $45 million, $(1) million, $83 million, and $53 million for the three months and years ended December 31, 2025 and 2024, respectively. The three months and year ended December 31, 2024 also includes $12 million and $25 million of amortization of the inventory step-up resulting from acquisitions.
(2)	For the year ended December 31, 2025, represents a settlement adjustment of $(8) million related to the ethylene oxide (“EtO”) litigation, $(43) million related to settlement of an intellectual property dispute, and other legal settlements. For the year ended December 31, 2024, represents $2 million related to one-time legal costs. The three months ended December 31, 2025 includes $14 million related to other legal settlements.
(3)	For the three months and years ended December 31, 2025 and 2024, respectively, includes $5 million, $10 million, $28 million, and $22 million of acquisition and integration-related costs and adjustments; and $18 million, $5 million, $30 million and $9 million of expenses related to our IPO, consisting of legal, accounting, and advisory fees, as well as one-time employee bonuses, including those with an ongoing service requirement. The three months and year ended December 31, 2024 also includes $(6) million and $(13) million of one-time gain related to acquisition of equity investment, respectively.
(4)	For the three months and years ended December 31, 2025 and 2024, respectively, includes $(4) million, $(32) million, $87 million, and $(6) million of realized and unrealized foreign exchange and investment losses (gains); $58 million, $13 million, $64 million, and $56 million of loss on debt extinguishment and other refinancing costs and fees; $(1) million, $22 million, $31 million, and $38 million credit loss expense (recovery) related to certain customer receivables; and $5 million, $3 million, $20 million, and $23 million of other project costs.
(5)	Not Meaningful.

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
(unaudited)

($ millions)	Year ended
	December 31, 2025				December 31, 2024				$ Change				% Change
Net cash provided by operating activities	$	1,744			$	1,769			$	(25	)		(1.4)%
Net capital expenditures		(447	)			(354	)			(93	)		26.3%
Free Cash Flow	$	1,297			$	1,415			$	(118	)		(8.3)%

FAQ

What were Medline (MDLN) fourth quarter 2025 sales and net income?

Q4 2025 net sales were $7.8 billion and net income was $180 million. According to the company, sales rose 14.8% year-over-year while net income fell 37.7% due to tariffs, higher operating costs, and IPO-related expenses.

How did Medline (MDLN) perform for the full year 2025 financially?

Full year 2025 net sales were $28.4 billion with Adjusted EBITDA of $3.5 billion. According to the company, sales rose 11.5% while net income declined 3.6%, driven by higher costs and investments.

What guidance did Medline (MDLN) give for full year 2026 on February 25, 2026?

Medline expects 2026 Organic Sales growth of 8%–9% and Adjusted EBITDA of $3.5–$3.6 billion. According to the company, guidance is provided on a non-GAAP basis due to comparability uncertainties.

What caused Medline's profit decline despite higher sales in 2025?

Profit was pressured by higher costs of goods sold from tariffs and increased operating expenses. According to the company, IPO-related costs, investments in headcount, and tariff-driven inventory costs partially offset higher net sales.

How much cash flow did Medline (MDLN) generate in 2025 and what drove it?

Net cash provided by operations was $1.7 billion and Free Cash Flow was $1.3 billion. According to the company, cash was driven by net income and non-cash items, offset by working capital and capital expenditures.

Did Medline announce any major commercial momentum in 2025 for investors?

Yes; the company reported $2.4 billion in total new customer signings during 2025. According to the company, this reflects expanded customer contracts and demand across Medline Brand and Supply Chain Solutions.